Phaseline

Targets › BDNF

BDNF (Neurotrophic factor BDNF precursor form): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 1; Neurology; next expected readout Jul 2028.

Important signaling molecule that activates signaling cascades downstream of NTRK2. During development, promotes the survival and differentiation of selected neuronal populations of the peripheral and central nervous systems. (UniProt, P23560)

Open in Phaseline: the race on BDNF, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Mark TuszynskiAAV2-BDNF
AAV2-mediated gene therapy expressing human BDNF
BDNFPhase 1Alzheimer's DiseaseJul 2028
BnH ResearchBnH-015B
GluN2B-selective NMDA receptor positive allosteric modulator; regulates BDNF/TRKβ and micr
GRIN2B, BDNF, NTRK2Phase 1Alzheimer Disease–

Conditions

Alzheimer's Disease (1) Alzheimer Disease (1)

Modalities

other (1), small molecule (1)

Companies

Mark Tuszynski (1) BnH Research (1)

Related targets

GRIN2B (1) NTRK2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.